DUPLEX For Use with Cefotetan Approved by U.S. Food and Drug Administration.

DUPLEX([R]) Premium Drug Delivery System Enables Safe, Accurate IV Administration of Antibiotic Therapy

BETHLEHEM, Pa. -- B. Braun Medical Inc., a global leader in innovative healthcare products and services, today announced the U. S. Food and Drug Administration (FDA) approved Cefotetan for Injection and Dextrose for Injection in the DUPLEX([R]) Drug Delivery System. With a unique design that helps ensure accurate dosage delivery and allows for room-temperature storage, DUPLEX is now the only ready-to-use IV drug delivery system available for Cefotetan therapy in the United States.

"Cefotetan is a critical antibiotic, and we are committed to ensuring a safe and easy-to-use drug delivery system for Cefotetan is available to hospitals nationwide," said Rick Williamson, Director of Marketing, Drug Delivery, B. Braun Medical Inc. "The DUPLEX system is designed to alleviate pharmacist and caregiver workload while protecting patients from potential medication errors, helping hospitals to reduce labor costs and improve patient safety."

DUPLEX, a dual chamber IV container, stores the drug and diluent in separate compartments until the seal is broken just prior to administration, helping clinicians comply with The Joint Commission and USP <797> Guidelines that specify medicines should be dispensed in their "most ready-to-use form." The system is also equipped with a unique barcode system that references the final admixture and can be used to reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

"If IV medications are not properly activated, they can be administered only partially or not administered at all, putting patients at risk," said Arash Dabestani, PharmD, MHA, Director of Pharmacy Services, Potomac Hospital. "DUPLEX helps to prevent inaccurate administration through its intelligent, easy-to-use design, which also eliminates drug waste and reduces distribution time--helping our institution to save time, money and patient lives."

B. Braun anticipates that Cefotetan in the DUPLEX Drug Delivery System will be available in September 2007, and is currently accepting preorders. B. Braun can be reached at 1-800-BBRAUN-2 (800-227-2862).

With the addition of Cefotetan to its drug delivery portfolio, B. Braun now offers a broad spectrum of intravenous cephalosporin antibiotic therapies for the hospital setting: Cefoxitin, CefTRIaxONE, Cefazolin, CefUROXime and Cefotetan.

About DUPLEX

The DUPLEX Drug Delivery System is a closed system that ensures sterility and dose accuracy. It consists of a pre-filled, latex- and PVC/DEHP-free IV bag containing accurate doses of drug and diluent in different compartments, separated by a quick release seal. There are no vials to attach or activate, and there is no possibility of delivering the diluent without the drug. Prior to activation, it can be stored at room temperature for up to 12 months and does not require a thawing process.

About B. Braun

B. Braun is the recipient of the 2007 Frost & Sullivan Medical Technology Global Excellence Award for its excellence in helping healthcare providers improve the lives of their patients.

Since its founding in 1839, B. Braun has built an unparalleled store of knowledge and expertise in delivering innovative healthcare products, medical devices and programs that enhance working processes in hospitals, alternate care settings and medical practices - increasing safety for patients, doctors and nurses. Its 34,000 employees worldwide are proud of their commitment to translating customer needs into products with unmatched quality, superior technology, cost-effectiveness and environmental responsibility.

Through its "Sharing Expertise([R])" initiative, B. Braun promotes best practices for continuous improvement of healthcare products and services. For more information about B. Braun or its safety healthcare products, call 800-854-6851, email us at [e-mail] or visit B. Braun at www.bbraunusa.com.